| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 (NCT03185494) | Chinese PLA General Hospital | 2017-08-01 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 (NCT03097770) | Chinese PLA General Hospital | 2017-04-01 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (NCT02281279) | Mayo Clinic | 2016-10-01 |
| Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (NCT02721407) | Xinqiao Hospital of Chongqing | 2016-03-01 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (NCT02685670) | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 2016-02-01 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (NCT02652910) | Xinqiao Hospital of Chongqing | 2015-12-01 |
| Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma (NCT02303392) | Jennifer Woyach | 2015-06-09 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (NCT01769911) | Fred Hutchinson Cancer Center | 2015-02-01 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT02168907) | Wake Forest University Health Sciences | 2014-12-01 |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT02240719) | University of California, Davis | 2014-10-01 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (NCT02109224) | National Cancer Institute (NCI) | 2014-09-01 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (NCT01959477) | Case Comprehensive Cancer Center | 2014-03-01 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT01652014) | University of Medicine and Dentistry of New Jersey | 2014-01-01 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT01748721) | Morphotek | 2013-11-01 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (NCT01815749) | City of Hope Medical Center | 2013-10-08 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01812005) | Ohio State University Comprehensive Cancer Center | 2013-05-21 |
| Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma (NCT01722305) | Mayo Clinic | 2013-04-08 |
| Ipilimumab and Local Radiation for Selected Solid Tumors (NCT01769222) | Stanford University | 2013-02-01 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy (NCT01735604) | Chinese PLA General Hospital | 2013-01-01 |
| Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01719250) | Mayo Clinic | 2012-12-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL (NCT01686165) | University of Arizona | 2012-08-31 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant (NCT01475058) | Fred Hutchinson Cancer Center | 2012-04-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT01434472) | Fred Hutchinson Cancer Center | 2011-11-16 |
| Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma (NCT01397591) | OHSU Knight Cancer Institute | 2011-10-01 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (NCT01427881) | Fred Hutchinson Cancer Center | 2011-09-01 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma (NCT02037256) | Barbara Ann Karmanos Cancer Institute | 2011-07-01 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors (NCT01326702) | National Cancer Institute (NCI) | 2011-07-01 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (NCT01658319) | Case Comprehensive Cancer Center | 2011-05-01 |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01261247) | Mayo Clinic | 2011-01-17 |
| Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma (NCT01075321) | Mayo Clinic | 2011-01-10 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma (NCT01258998) | National Cancer Institute (NCI) | 2010-12-01 |
| Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT01278615) | National Cancer Institute (NCI) | 2010-12-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma (NCT01165112) | University of Washington | 2010-09-01 |
| Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (NCT01110135) | University of Washington | 2010-08-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01076270) | Fred Hutchinson Cancer Center | 2010-06-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (NCT01116154) | City of Hope Medical Center | 2010-05-01 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy (NCT01029366) | University of Pennsylvania | 2010-03-17 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma (NCT01045928) | Case Comprehensive Cancer Center | 2010-01-01 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (NCT01044745) | University of Nebraska | 2009-12-10 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00769288) | National Cancer Institute (NCI) | 2009-07-01 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT00891072) | National Cancer Institute (NCI) | 2009-07-01 |
| Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (NCT00918333) | Mayo Clinic | 2009-06-01 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (NCT00867529) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma (NCT00538187) | National Cancer Institute (NCI) | 2007-12-01 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (NCT00601718) | University of Washington | 2007-12-01 |
| Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01093586) | Case Comprehensive Cancer Center | 2007-09-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (NCT00499811) | National Cancer Institute (NCI) | 2007-06-01 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma (NCT00458731) | National Cancer Institute (NCI) | 2007-05-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma (NCT00392496) | National Cancer Institute (NCI) | 2007-02-01 |
| FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00383565) | National Cancer Institute (NCI) | 2006-09-01 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (NCT00536601) | Roswell Park Cancer Institute | 2006-06-29 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00293345) | National Cancer Institute (NCI) | 2006-06-01 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma (NCT00354185) | National Cancer Institute (NCI) | 2006-05-01 |
| A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (NCT00343798) | Fred Hutchinson Cancer Center | 2006-04-01 |
| Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00109824) | National Cancer Institute (NCI) | 2006-03-01 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00348985) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia (NCT00275080) | National Cancer Institute (NCI) | 2006-02-01 |
| PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT00303953) | National Cancer Institute (NCI) | 2006-01-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (NCT00112723) | National Cancer Institute (NCI) | 2005-12-01 |
| Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma (NCT00131937) | National Cancer Institute (NCI) | 2005-10-01 |
| Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (NCT00278382) | National Cancer Institute (NCI) | 2005-10-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00118352) | Fred Hutchinson Cancer Center | 2005-03-01 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00105001) | Fred Hutchinson Cancer Center | 2004-11-01 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma (NCT00101244) | National Cancer Institute (NCI) | 2004-11-01 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00096005) | National Cancer Institute (NCI) | 2004-11-01 |
| Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma (NCT00438880) | Mayo Clinic | 2004-10-01 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (NCT00098891) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function (NCT00118170) | National Cancer Institute (NCI) | 2004-10-01 |
| 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas (NCT00089271) | National Cancer Institute (NCI) | 2004-07-01 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (NCT00089076) | National Cancer Institute (NCI) | 2004-06-01 |
| Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00119392) | Fred Hutchinson Cancer Center | 2004-06-01 |
| Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (NCT00086944) | National Cancer Institute (NCI) | 2004-05-01 |
| CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00086840) | National Cancer Institute (NCI) | 2004-05-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms (NCT00082784) | National Cancer Institute (NCI) | 2004-03-01 |
| CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (NCT00290472) | National Cancer Institute (NCI) | 2004-03-01 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00077155) | National Cancer Institute (NCI) | 2003-12-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies (NCT00072514) | Fred Hutchinson Cancer Center | 2003-08-01 |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder (NCT00064246) | National Cancer Institute (NCI) | 2003-07-01 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (NCT00060372) | National Cancer Institute (NCI) | 2003-04-01 |
| Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation (NCT00058305) | National Cancer Institute (NCI) | 2003-03-01 |
| Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma (NCT00060112) | National Cancer Institute (NCI) | 2003-03-01 |